BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
URL: http://ajpr1.umsha.ac.ir/article-1-39-en.html
, Masoud Hafizi2 , Ali Baradaran2 , Keyhan Ghatreh-Samani3 , Roohollah Mohseni3 , Akbar Soleimani2
2- Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran
3- Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
Background: COVID-19 became widespread in 2019 worldwide and affected everyone. Even though it was a disease caused by a new strain of coronavirus with severe symptoms, some drugs could be effective in its treatment. It seems that methylene blue (MB), a drug for treating methemoglobinemia, can be a useful COVID-19 treatment.
Methods: Overall, 60 COVID-19 patients with an O2 saturation of less than 85% and with no underlying diseases were chosen and included in this study. The patients were divided into the placebo control group (n=30) and the MB-treated group (n=30) and received 1 mg/kg of MB for 4 days. Some serum parameters were measured before and after 4 days of treatment. In addition, the O2 saturation was measured every 12 hours. Then, the results were compared with each other.
Results: MB decreased the serum C-reactive protein (P=0.14), lactate dehydrogenase (P=0.08), and creatinine (P=0.12) in the COVID-19 patients non-significantly and increased the serum aspartate aminotransferase (P=0.40) and alanine aminotransferase (P=0.36) parameters in comparison with the control placebo group. However, it had no significant effect on O2 saturation (P=0.52) in COVID-19 patients.
Conclusion: MB, a specific drug for treating methemoglobinemia, had no significant effect on COVID-19 patients.
Received: 2026/09/28 | Accepted: 2024/02/29 | Published: 2026/09/28
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
